Key facts
- This page summarizes Louis G. Lange's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2026, 16:25.
Louis G. Lange - 11 Mar 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- Director
- Issuer ticker
- NAMS
- Reported as of
- 11 Mar 2026
- Net transaction value
- -$1,357,230
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2026, 16:25:23 UTC
- Prior SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louise Kooij by Power of Attorney from Louis G. Lange
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Louis G. Lange filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 12 Mar 2026.
Change
- Previous filing in this sequence was filed on 10 Mar 2026.
- Current net transaction value: -$1,357,230.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001238401
Primary reporting owner
LANGE LOUIS G
- Relationship
- Director
- Address
- C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
- Signature
- /s/ Louise Kooij by Power of Attorney from Louis G. Lange
- Signature date
- 12 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
transaction
Ordinary Shares
Sale
- Transaction value
- $1,343,301
- Shares
- -44,173
- Change %
- -80%
- Price
- $30.41
- Shares after
- 10,806
- Date
- 11 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
NAMS
transaction
Ordinary Shares
Sale
- Transaction value
- $13,929
- Shares
- -446
- Change %
- -4.1%
- Price
- $31.23
- Shares after
- 10,360
- Date
- 11 Mar 2026
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.